Accumulating evidence has shown that simultaneous inactivation of the DRD2/3 signaling pathway can have therapeutic effects in cancer patients such as pancreatic cancer, as suggested by the anti-tumor effects of ONC201 [25,26,27]. This evidence concerns the gene DRD2 and familial pancreatic carcinoma.